Literature DB >> 24002765

Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer.

Alan A Thomay1, David M Nagorney, Steven J Cohen, Elin R Sigurdson, Mark J Truty, Barbara Burtness, Michael J Hall, Yun Shin Chun.   

Abstract

BACKGROUND: In colorectal cancer, the involvement of regional lymph nodes with metastasis is an established prognostic factor. The impact of the number of positive nodes on patient outcome with stage IV disease is not well defined.
METHODS: A retrospective review was performed of 1,421 patients at two tertiary referral centers with stage IV colorectal cancer who underwent primary tumor resection. Associations between regional nodes, lymph node ratio (LNR), and overall survival (OS) from date of diagnosis were analyzed.
RESULTS: The number of positive regional nodes and LNR correlated with multiple sites of metastases (p < 0.001). Survival was significantly associated with the number of positive nodes and LNR, with a median OS of 43 months with negative nodes, compared to 20 months with ≥7 positive nodes (p < 0.001). The number of regional nodal metastases correlated with OS among 400 patients undergoing resection of liver metastases (p = 0.005) but lost prognostic significance in the subset of 223 patients who underwent hepatectomy with perioperative oxaliplatin- or irinotecan-based chemotherapy (p = 0.48).
CONCLUSIONS: In stage IV colorectal cancer, an increasing number of positive regional nodes and LNR correlate with multiple sites of metastases and poorer survival. The number of metastatic regional lymph nodes loses prognostic significance with modern chemotherapy in patients undergoing resection of liver metastases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24002765     DOI: 10.1007/s11605-013-2329-8

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  15 in total

1.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

Authors:  Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

2.  Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy.

Authors:  Peter Kornprat; William R Jarnagin; Mithat Gonen; Ronald P DeMatteo; Yuman Fong; Leslie H Blumgart; Michael D'Angelica
Journal:  Ann Surg Oncol       Date:  2006-12-31       Impact factor: 5.344

3.  Assessment of prognostic factors after primary tumor resection in metastatic colon cancer patients: a Veteran's Affairs Central Cancer Registry (VACCR) analysis, 1995-2008.

Authors:  Wilson I Gonsalves; Joseph Wolpert; Tsewang Tashi; Apar K Ganti; Shanmuga Subbiah; Charles Ternent; Peter T Silberstein
Journal:  J Surg Oncol       Date:  2012-03-27       Impact factor: 3.454

4.  Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.

Authors:  Adam C Berger; Elin R Sigurdson; Thomas LeVoyer; Alexandra Hanlon; Robert J Mayer; John S Macdonald; Paul J Catalano; Daniel G Haller
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

5.  N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma.

Authors:  Nakul P Valsangkar; Devon M Bush; James S Michaelson; Cristina R Ferrone; Jennifer A Wargo; Keith D Lillemoe; Carlos Fernández-del Castillo; Andrew L Warshaw; Sarah P Thayer
Journal:  J Gastrointest Surg       Date:  2012-12-11       Impact factor: 3.452

6.  Detailed pathologic characteristics of the primary colorectal tumor independently predict outcome after hepatectomy for metastases.

Authors:  Kenneth Cardona; Pedro Mastrodomenico; Francesco D'Amico; Jinru Shia; Mithat Gönen; Martin R Weiser; Philip B Paty; T Peter Kingham; Peter J Allen; Ronald P De Matteo; Yuman Fong; William R Jarnagin; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2012-07-31       Impact factor: 5.344

7.  A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer.

Authors:  Michael W Kattan; Mithat Gönen; William R Jarnagin; Ronald DeMatteo; Michael D'Angelica; Martin Weiser; Leslie H Blumgart; Yuman Fong
Journal:  Ann Surg       Date:  2008-02       Impact factor: 12.969

8.  Hepatic resection for colorectal metastases: value for risk scoring systems?

Authors:  Shaheen Zakaria; John H Donohue; Florencia G Que; Michael B Farnell; Cathy D Schleck; Duane M Ilstrup; David M Nagorney
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

9.  Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

Authors:  Dan G Blazer; Yoji Kishi; Dipen M Maru; Scott Kopetz; Yun Shin Chun; Michael J Overman; David Fogelman; Cathy Eng; David Z Chang; Huamin Wang; Daria Zorzi; Dario Ribero; Lee M Ellis; Katrina Y Glover; Robert A Wolff; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544

10.  A study of lymph node ratio in stage IV colorectal cancer.

Authors:  Kristoffer Derwinger; Bengt Gustavsson
Journal:  World J Surg Oncol       Date:  2008-12-01       Impact factor: 2.754

View more
  4 in total

1.  Association between the lymph node ratio and hepatic tumor burden: importance for resectable colorectal liver metastases?

Authors:  Kristoffer Watten Brudvik; Kjetil Søreide
Journal:  Hepatobiliary Surg Nutr       Date:  2018-06       Impact factor: 7.293

Review 2.  Application of radiation technology in vaccines development.

Authors:  Ho Seong Seo
Journal:  Clin Exp Vaccine Res       Date:  2015-07-29

3.  ALPPS versus two-stage hepatectomy for colorectal liver metastases--a comparative retrospective cohort study.

Authors:  Jan Bednarsch; Zoltan Czigany; Samara Sharmeen; Gregory van der Kroft; Pavel Strnad; Tom Florian Ulmer; Peter Isfort; Philipp Bruners; Georg Lurje; Ulf Peter Neumann
Journal:  World J Surg Oncol       Date:  2020-06-24       Impact factor: 2.754

4.  pH-Responsive Cross-Linked Low Molecular Weight Polyethylenimine as an Efficient Gene Vector for Delivery of Plasmid DNA Encoding Anti-VEGF-shRNA for Tumor Treatment.

Authors:  Xiaoming Li; Xiaoshuang Guo; Yuan Cheng; Xiaotian Zhao; Zhiwei Fang; Yanli Luo; Shujun Xia; Yun Feng; Jianjun Chen; Wei-En Yuan
Journal:  Front Oncol       Date:  2018-09-25       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.